Recent investigations indicate that IFN‐γ is an important promoter of the programmed PD‐L1 expression in cancer cells and host cells, and the infiltrating data line of T cells in tumors can raise the possibility of a response to anti‐PD‐1 therapies, including pembrolizumab.35 This evidence concerns the gene CD274 and cancer.